Prostate Cancer Clinical Trial
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Summary
The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
Eligibility Criteria
Inclusion Criteria:
Histologic confirmation of adenocarcinoma of the prostate
Evidence of stage IV disease on previous bone, CT, and/or MRI scan
Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy
Mandatory plasma and fresh or archival tumor tissue must be submitted
Exclusion Criteria:
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast
Participants with active brain metastases
Participants must have recovered from the effects of major surgery requiring general anesthesia or significant traumatic injury at least 14 days before treatment arm assignment
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 63 Locations for this study
Daphne Alabama, 36526, United States
Rancho Mirage California, 92270, United States
New Haven Connecticut, 06520, United States
Miami Florida, 33176, United States
Marietta Georgia, 30060, United States
Louisville Kentucky, 40207, United States
New Orleans Louisiana, 70112, United States
Rockville Maryland, 20850, United States
Boston Massachusetts, 02118, United States
Detroit Michigan, 48201, United States
Jackson Mississippi, 39202, United States
Saint Louis Missouri, 63110, United States
Omaha Nebraska, 68130, United States
Albany New York, 12208, United States
New York New York, 10032, United States
Durham North Carolina, 27710, United States
Portland Oregon, 97225, United States
Allentown Pennsylvania, 18103, United States
Fairfax Virginia, 22031, United States
Caba Buenos Aires, 1426, Argentina
Capital Federal Buenos Aires, 1426, Argentina
Villa Siburu Cordoba, 5003, Argentina
Ciudad Autonoma de Buenos Aires Distrito Federal, C1280, Argentina
Caba , 1199, Argentina
Camperdown New South Wales, 2050, Australia
Westmead New South Wales, 2145, Australia
South Brisbane Queensland, 4101, Australia
Elizabeth Vale South Australia, 5112, Australia
Clayton Victoria, 0, Australia
Heidelberg Victoria, 3084, Australia
Belo Horizonte Minas Gerais, 30110, Brazil
Belo Horizonte Minas Gerais, 30130, Brazil
Curitiba Parana, 81480, Brazil
Ijui RIO Grande DO SUL, 98700, Brazil
Porto Alegre RIO Grande DO SUL, 90035, Brazil
Campinas SAO Paulo, 13075, Brazil
São Paulo SAO Paulo, 05652, Brazil
Rio de Janeiro , 22793, Brazil
Sao Paulo , 01308, Brazil
Kelowna British Columbia, V1Y 5, Canada
Moncton New Brunswick, E1C 6, Canada
Hamilton Ontario, L8V 5, Canada
Montreal Quebec, H2X 0, Canada
Quebec , G1R 3, Canada
Santiago Metropolitana, 84203, Chile
Vina del Mar Valparaiso, 25403, Chile
Monteria Cordoba, 0, Colombia
Medellin , 0, Colombia
Besancon , 25030, France
Clermont-ferrand , 63000, France
Lyon , 69008, France
Marseille , 13273, France
Villejuif , 94800, France
Essen , 45122, Germany
Goettingen , 37075, Germany
Heidelberg , D-691, Germany
Jena , 07747, Germany
Koblenz , 56068, Germany
Muenchen , 81675, Germany
Leon Guanajuato, 37000, Mexico
Guadalajara Jalisco, 44130, Mexico
Guadalajara Jalisco, 44280, Mexico
Culiacan Sinaloa, 80230, Mexico
Madrid , 28041, Spain
Pamplona , 31008, Spain
Sevilla , 41013, Spain
How clear is this clinincal trial information?